Drug class profile · refreshed daily from federal data

Cholinergic Muscarinic Antagonist

5 molecules in this class, $457.1M combined CY2024 Part D spend across 12.5M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Cholinergic Muscarinic Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: $457.1Mcombined across class
Total Rx claims: 12.5M4.1M unique beneficiaries
Generic mfrs (active): 60across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Oxybutynin

Brand: OXYTROL · 8.1M Part D claims (CY24) · 2.6M beneficiaries · First FDA approval: 1990-09-30

21 generic mfrs 10 plans require PA Discontinued

Low NADAC$0.032

→

Avg plan cost$1.02

Part D spend $174.7M 32× spread, current vs floor

Class share

38%

of class CY24 spend

View profile →

Solifenacin

Brand: VESIcare · 2.2M Part D claims (CY24) · 743K beneficiaries · First FDA approval: 2005-01-05

17 generic mfrs 4 plans require PA

Low NADAC$0.173

→

Avg plan cost$0.805

Part D spend $109.6M 5× spread, current vs floor

Class share

24%

of class CY24 spend

View profile →

Tolterodine

Brand: Detrol · 1.2M Part D claims (CY24) · 387K beneficiaries · First FDA approval: 2014-01-21

12 generic mfrs 8 plans require PA

Low NADAC$0.200

→

Avg plan cost$0.246

Part D spend $100.4M 1× spread, current vs floor

Class share

22%

of class CY24 spend

View profile →

Trospium

915K Part D claims (CY24) · 339K beneficiaries · First FDA approval: 2010-08-13

10 generic mfrs 4 plans require PA

Low NADAC$0.220

→

Avg plan cost$0.710

Part D spend $72.4M 3× spread, current vs floor

Class share

16%

of class CY24 spend

View profile →

Darifenacin

— Part D claims (CY24) · First FDA approval: 2016-09-19

Brand-only (no generics) 0 plans require PA

Low NADAC$0.401

→

Avg plan cost$0.484

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.